Replies to post #3466 on GTC Biotherapeutics (fka GTCB)

[DewDiligence]

>Why shouldn't Novo attempt to buy GTC, given the prospective economics [of NovoSeven] beyond 2012?<

Good question.

NVO is working on a follow-on to NovoSeven called NN1731 (#msg-18366299); however, with much less risk, NVO could acquire a patent-protected rFVIIa product from GTC and the rest of the company’s assets to boot.

When we talk about whether GTC will reach profitability in mid 2008, we have to keep in mind that GTC may not be a standalone business by that time.